
BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds - 2
No respite for German economy as experts slash forecast over Iran war - 3
Surveys of Music Collections by Film Stars - 4
A top Marine shares his secrets to keeping fit at 50 - 5
Polar bears are rewiring their own genetics to survive a warming climate
Holiday destinations for Creature Sweethearts
The 15 Most Compelling Books in History
Most loved Solace Food: What's Your Definitive Comfortable Dinner?
Former defense minister Gallant vacated home over security threat under Shin Bet direction
'Not the moon that I'm used to seeing': Artemis II astronauts describe seeing the far side
Warming winters lead to more nitrate pollution in the drinking water near farms
Exclusive new photos from 'Michael' biopic show Jaafar Jackson as King of Pop
Regeneron's experimental therapy combo effective in untreated cancer patients
A definitive Manual for the 5 Off-road Bicycles Available













